Signal transduction in G0/G1-arrested mouse Y1 adrenocortical cells stimulated by ACTH and FGF2

A P Lepique1, F L Forti, M S Moraes

  • 1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Brasil.

Endocrine Research
|February 24, 2001
PubMed

Insights

Adrenocorticotropic hormone (ACTH) inhibits fibroblast growth factor 2 (FGF2) induced cell proliferation in Y1 cells. This occurs via cAMP/PKA signaling, downregulating c-Myc and dephosphorylating AKT/PKB.

Area of Science:

  • Cell Biology
  • Molecular Endocrinology
  • Cancer Research

Background:

  • Adrenocorticotropic hormone (ACTH) and fibroblast growth factor 2 (FGF2) have opposing effects on Y1 adrenocortical tumor cell proliferation.
  • ACTH acts as an anti-mitogenic agent, while FGF2 is mitogenic, with FGF2's effects occurring at the G1 phase of the cell cycle.

Purpose of the Study:

  • To elucidate the anti-mitogenic mechanisms of ACTH in Y1 cells, specifically how it counteracts FGF2-induced proliferation.
  • To investigate the roles of c-Myc and AKT/PKB signaling pathways in ACTH's anti-mitogenic effects.

Main Methods:

  • Y1 adrenocortical tumor cells were used, some with PKA deficiency.
  • Experiments involved cell cycle arrest, mitogen stimulation (ACTH and FGF2), protein analysis (c-Myc, AKT/PKB), and gene manipulation (MycER chimera).
  • Specific inhibitors (PD98059, Wortmannin) and signaling pathway activators (Ras x GTP) were employed.

Main Results:

  • ACTH, mediated by cAMP/PKA, downregulates c-Myc post-transcriptionally and dephosphorylates AKT/PKB, counteracting FGF2's pro-mitogenic signaling.
  • FGF2 stabilizes c-Myc via ERK-MAPK and upregulates AKT/PKB through PI3K, while ACTH inhibits these effects.
  • Restoration of c-Myc levels via MycER chimera reversed ACTH's anti-mitogenic effect on DNA synthesis.

Conclusions:

  • ACTH employs dual anti-mitogenic mechanisms involving c-Myc downregulation and AKT/PKB dephosphorylation, both initiated via ACTH receptors and cAMP/PKA.
  • The Mad/Max/Myc transcription factor network's activity is sensitive to c-Myc levels in Y1 cells.
  • Targeting these pathways could offer strategies for controlling adrenocortical tumor cell proliferation.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...